FDA Approves NEXUS Aortic Arch Stent Graft System for Minimally Invasive Treatment of Complex Aortic Disease
核心洞察
The FDA has approved Endospan (搜索)'s NEXUS Aortic Arch Stent Graft System (搜索), marking the first endovascular off-the-shelf solution for treating aortic arch disease (搜索) including chronic aortic dissections (搜索).
The TRIOMPHE IDE study demonstrated strong clinical outcomes with 90% patient survival from lesion-related death and 90% freedom from disabling stroke at one year in high-risk patients.
The approval addresses a significant unmet medical need, as more than 120,000 patients suffer from thoracic aortic arch disease (搜索) annually in the U.S. and Europe, with only 25% currently diagnosed or treated.
The U.S. Food and Drug Administration has approved the NEXUS Aortic Arch Stent Graft System (搜索), developed by Israeli company Endospan (搜索), providing the first minimally invasive endovascular solution for treating aortic arch disease (搜索), including chronic aortic dissections (搜索). The approval represents a significant breakthrough for patients who previously had limited treatment options beyond high-risk open-chest surgery.
Clinical Evidence Supporting Approval
FDA approval was supported by one-year results from the TRIOMPHE Investigational Device Exemption (IDE) Study, a prospective, multicenter trial evaluating the NEXUS System in high-risk surgical patients. The study demonstrated compelling clinical outcomes, with 90% patient survival from lesion-related death, 90% freedom from disabling stroke at one year post-treatment, and 98% freedom from reintervention due to endoleaks at one year.
The trial specifically focused on high-risk surgical patients with chronic dissections, demonstrating safe and effective treatment in the ascending aorta (搜索), which Brad Leshnower, national cardiac surgery co-principal investigator, described as "a very difficult segment of the aorta to treat without high rates of co-morbidities such as mortality or stroke."
Addressing Significant Unmet Medical Need
More than 120,000 patients suffer from thoracic aortic arch disease (搜索) every year in the U.S. and Europe, with only about 25% diagnosed or treated. Despite significant advancements in cardiovascular medicine, patients with excessive risk or anatomical factors might not be indicated for surgery, yet anatomical complexity and lack of approved devices for the arch have often prohibited endovascular repair.
"This makes the choice of treatment difficult or even impossible for some patients," according to the clinical data. The NEXUS System addresses this gap by providing a transcatheter repair alternative that expands treatment options for the aortic community.
Technical Innovation and Design
The NEXUS System is a bimodular system specifically designed to mimic the ascending and arch anatomy. Key technical features include the lowest profile 20F delivery system with a pre-shaped catheter that allows one pass into the arch to minimize arch manipulation, and an integrated branch designed for hemodynamic efficiency.
"The anatomical design of the NEXUS System addresses many of the complexities that occur when treating the ascending and aortic arch (搜索)," said Leshnower. "I am pleased to now be able to offer this minimally invasive solution to patients with life threatening diseases involving the ascending aorta (搜索) and arch who are at high risk for conventional open repair."
Commercial and Strategic Implications
The approval enables immediate U.S. commercial launch of the NEXUS System by Endospan (搜索). Additionally, Artivion, Inc., Endospan's long-standing partner, holds an option to acquire the Israeli company within 90 days of FDA approval. Artivion has proactively secured a $150 million delayed draw term loan to fund the potential acquisition.
"NEXUS receiving FDA approval ahead of our expectations is an exciting milestone for patients with aortic arch disease (搜索), for our partner Endospan (搜索), and for Artivion," said Pat Mackin, Artivion's Chairman, President, and Chief Executive Officer. "The TRIOMPHE data has consistently demonstrated the clinical value of this technology."
Kevin Mayberry, Endospan (搜索)'s CEO, emphasized the significance of the milestone: "NEXUS was designed specifically for the ascending and aortic arch (搜索). The TRIOMPHE one-year data and pre-and-post commercialization data from the EU demonstrate that this is a viable alternative for patients with arch disease."
Global Market Position
Endospan (搜索)'s NEXUS System previously received CE Mark approval for commercialization in Europe, making it the first endovascular off-the-shelf system to treat aortic arch disease (搜索) in that market. The FDA approval now extends this innovative treatment option to U.S. patients, potentially transforming care for a patient population that has historically faced limited therapeutic alternatives beyond invasive open surgical procedures.